search
Back to results

Treatment of Breast Fibroadenoma With High Intensity Focused Ultrasound (HIFU) (HIFU)

Primary Purpose

Breast Fibroadenoma

Status
Completed
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
High Intensity Focused Ultrasound
Sponsored by
University Women's Hospital Tübingen
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Breast Fibroadenoma

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Female patients 18 years or older with at least one diagnosed breast fibroadenoma. Diagnosis of fibroadenoma must be based on:
  • clinical examination,
  • women ≤ 40 years of age: ultrasound image alone; women > 40 years of age: ultrasound image and mammogram,
  • histological confirmation of fibroadenoma of the breast. Patient's fibroadenoma size as determined by ultrasound imaging: the longest diameter is limited to 25 mm. Women of childbearing potential must have a negative urine pregnancy test within 72 hours prior to HIFU treatment. Patient must be able to understand the nature and the extent of the study and the procedures required and be willing and able to complete the screening and study procedures. Patient must give written informed consent (personally signed and dated) before completing any study-related procedure.

Exclusion Criteria:

  • Patient who is pregnant or breast-feeding.
  • Patient with history of ipsilateral breast cancer within 5 years prior to study inclusion or radio therapy to the target breast within 5 years prior to study inclusion.
  • Patient with implant on the treated breast.
  • Patient with target fibroadenoma pre-treated by cryoablation or interstitial laser therapy within 12 month before recruiting for HIFU.
  • Patient's fibroadenoma not clearly visible on the ultrasound images (in B mode) at the inclusion visit. Patient participating in other studies using drugs or medical devices within 3 months prior to study inclusion or during study participation including the follow-up period.

Sites / Locations

  • Department for Women's Health

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Treatment with high-intensity focused ultrasound

Arm Description

Outcomes

Primary Outcome Measures

The efficacy is assessed by a reduction in volume of the fibroadenoma at baseline, 6 months and at 12 months after the HIFU on the ultrasonography.
A reduction in volume of > 65% compared to baseline, or a total regression of the fibroadenoma will be taken as effective treatment. The results will be analyzed descriptively

Secondary Outcome Measures

Energy setting to obtain reduction in volume or total regression of the fibroadenoma at 12 months follow-up
Lack of palpable lesion
Pain free if pain at baseline (pain related to the fibroadenoma)
Gland vascularisation (compared to baseline) power Doppler at day 7, month 6 and 12 after the HIFU session
Pain during the HIFU session using a Visual Analog Pain Scale
Histological outcome through core needle biopsy after 12 month
Quality and ease of use of breast immobilization

Full Information

First Posted
July 1, 2015
Last Updated
January 19, 2017
Sponsor
University Women's Hospital Tübingen
Collaborators
Theraclion
search

1. Study Identification

Unique Protocol Identification Number
NCT03022695
Brief Title
Treatment of Breast Fibroadenoma With High Intensity Focused Ultrasound (HIFU)
Acronym
HIFU
Official Title
Treatment of Breast Fibroadenoma With High Intensity Focused Ultrasound (HIFU)
Study Type
Interventional

2. Study Status

Record Verification Date
June 2015
Overall Recruitment Status
Completed
Study Start Date
October 2013 (undefined)
Primary Completion Date
November 2015 (Actual)
Study Completion Date
December 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Women's Hospital Tübingen
Collaborators
Theraclion

4. Oversight

5. Study Description

Brief Summary
This is a monocenter, open-label, uncontrolled study in accordance with §23b MPG to evaluate the efficacy of the HIFU-treatment of fibroadenoma using the TH-One device.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Breast Fibroadenoma

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
27 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Treatment with high-intensity focused ultrasound
Arm Type
Experimental
Intervention Type
Device
Intervention Name(s)
High Intensity Focused Ultrasound
Primary Outcome Measure Information:
Title
The efficacy is assessed by a reduction in volume of the fibroadenoma at baseline, 6 months and at 12 months after the HIFU on the ultrasonography.
Description
A reduction in volume of > 65% compared to baseline, or a total regression of the fibroadenoma will be taken as effective treatment. The results will be analyzed descriptively
Time Frame
Baseline, 6 months, 12 months
Secondary Outcome Measure Information:
Title
Energy setting to obtain reduction in volume or total regression of the fibroadenoma at 12 months follow-up
Time Frame
1 year
Title
Lack of palpable lesion
Time Frame
2 years
Title
Pain free if pain at baseline (pain related to the fibroadenoma)
Time Frame
1 year
Title
Gland vascularisation (compared to baseline) power Doppler at day 7, month 6 and 12 after the HIFU session
Time Frame
Day 7, month 6, month 12
Title
Pain during the HIFU session using a Visual Analog Pain Scale
Time Frame
0 month
Title
Histological outcome through core needle biopsy after 12 month
Time Frame
1 year
Title
Quality and ease of use of breast immobilization
Time Frame
1 year

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Female patients 18 years or older with at least one diagnosed breast fibroadenoma. Diagnosis of fibroadenoma must be based on: clinical examination, women ≤ 40 years of age: ultrasound image alone; women > 40 years of age: ultrasound image and mammogram, histological confirmation of fibroadenoma of the breast. Patient's fibroadenoma size as determined by ultrasound imaging: the longest diameter is limited to 25 mm. Women of childbearing potential must have a negative urine pregnancy test within 72 hours prior to HIFU treatment. Patient must be able to understand the nature and the extent of the study and the procedures required and be willing and able to complete the screening and study procedures. Patient must give written informed consent (personally signed and dated) before completing any study-related procedure. Exclusion Criteria: Patient who is pregnant or breast-feeding. Patient with history of ipsilateral breast cancer within 5 years prior to study inclusion or radio therapy to the target breast within 5 years prior to study inclusion. Patient with implant on the treated breast. Patient with target fibroadenoma pre-treated by cryoablation or interstitial laser therapy within 12 month before recruiting for HIFU. Patient's fibroadenoma not clearly visible on the ultrasound images (in B mode) at the inclusion visit. Patient participating in other studies using drugs or medical devices within 3 months prior to study inclusion or during study participation including the follow-up period.
Facility Information:
Facility Name
Department for Women's Health
City
Tübingen
ZIP/Postal Code
72076
Country
Germany

12. IPD Sharing Statement

Learn more about this trial

Treatment of Breast Fibroadenoma With High Intensity Focused Ultrasound (HIFU)

We'll reach out to this number within 24 hrs